Akeso Reports Transformative Year with Remarkable Sales Growth in 2025
In its annual financial report for 2025, Akeso, Inc. (HKEX: 9926) has demonstrated extraordinary progress across its operations, emphasizing a significant leap in commercial sales and innovative product offerings. The company reported a record sales revenue of RMB 3,033.1 million, reflecting a 51.48% increase compared to the previous year. This phenomenal growth can be attributed to the successful inclusion of all approved products in China’s National Reimbursement Drug List (NRDL), alongside substantial clinical validation and positive reception from healthcare professionals and patients.
The year 2025 was notably transformative for Akeso, with several high-impact indications added to the NRDL, expanding its portfolio to include Ivonescimab for the first-line treatment of PD-L1-positive non-small cell lung cancer (NSCLC), Cadonilimab for first-line gastric and cervical cancers, and additional indications for penpulimab, ebdarokimab, and ebronucimab.
Akeso's innovative approach to oncology is anchored in its proprietary bispecific antibodies. Notably, Ivonescimab, the world's first approved PD-1/VEGF bispecific antibody, has provided groundbreaking therapeutic benefits to around 70,000 patients. Proven effectiveness has been showcased in multiple Phase III trials, particularly the HARMONi studies, where Ivonescimab outperformed existing standards of care, establishing new benchmarks in the treatment of NSCLC.
Similarly, Cadonilimab, known as the world’s first PD-1/CTLA-4 bispecific antibody, has been pivotal in treating various challenging cancers. With approximately 120,000 patients treated, it is recognized for its efficacy across different tumor types and stages, demonstrating both safety and effectiveness, thus becoming an integral part of the treatment landscape.
Looking ahead, Akeso is strategically expanding its clinical trials, with numerous Phase III studies underway for both Ivonescimab and Cadonilimab. This expansive global development agenda indicates Akeso’s commitment to addressing significant unmet medical needs and advancing therapeutic options for diverse cancer types. As part of its forward-thinking strategy, Akeso also unveiled its plan to explore trispecific antibodies and adopt cutting-edge ADC (antibody-drug conjugate) platforms to further enhance the therapeutic landscape.
Moreover, Akeso is making significant strides beyond oncology, targeting autoimmune, respiratory, and CNS diseases with innovative therapies powered by advanced dual-target strategies. The company’s integrated AI platforms play a crucial role in this development, ensuring efficient research and development processes from discovery to manufacturing.
Dr. Michelle Xia, founder and CEO of Akeso, remarked on the company’s 2025 achievements, stating, "This year marked a significant leap for Akeso in commercialization, global clinical expansion, and broadening our multi-platform innovation ecosystem. We are now set to pioneer new therapeutic paradigms by leveraging our leadership in bispecifics and expanding into innovative treatment modalities across various medical fields."
As Akeso continues to progress towards becoming a leader in the biopharmaceutical industry, it remains focused on delivering untapped therapeutic benefits to patients globally, ensuring its position as an innovative powerhouse in the development of groundbreaking medicines. With a robust pipeline of over 50 assets, including 27 candidates undergoing clinical trials, Akeso is committed to paving the way for future advancements in medicine and addressing critical healthcare challenges worldwide.
In summary, Akeso’s 2025 annual report not only highlights remarkable sales growth and strategic excellence but also underscores its ongoing commitment to innovation, enhancing patient outcomes, and leading a transformative change in the biopharmaceutical landscape.
The year 2025 was notably transformative for Akeso, with several high-impact indications added to the NRDL, expanding its portfolio to include Ivonescimab for the first-line treatment of PD-L1-positive non-small cell lung cancer (NSCLC), Cadonilimab for first-line gastric and cervical cancers, and additional indications for penpulimab, ebdarokimab, and ebronucimab.
Akeso's innovative approach to oncology is anchored in its proprietary bispecific antibodies. Notably, Ivonescimab, the world's first approved PD-1/VEGF bispecific antibody, has provided groundbreaking therapeutic benefits to around 70,000 patients. Proven effectiveness has been showcased in multiple Phase III trials, particularly the HARMONi studies, where Ivonescimab outperformed existing standards of care, establishing new benchmarks in the treatment of NSCLC.
Similarly, Cadonilimab, known as the world’s first PD-1/CTLA-4 bispecific antibody, has been pivotal in treating various challenging cancers. With approximately 120,000 patients treated, it is recognized for its efficacy across different tumor types and stages, demonstrating both safety and effectiveness, thus becoming an integral part of the treatment landscape.
Looking ahead, Akeso is strategically expanding its clinical trials, with numerous Phase III studies underway for both Ivonescimab and Cadonilimab. This expansive global development agenda indicates Akeso’s commitment to addressing significant unmet medical needs and advancing therapeutic options for diverse cancer types. As part of its forward-thinking strategy, Akeso also unveiled its plan to explore trispecific antibodies and adopt cutting-edge ADC (antibody-drug conjugate) platforms to further enhance the therapeutic landscape.
Moreover, Akeso is making significant strides beyond oncology, targeting autoimmune, respiratory, and CNS diseases with innovative therapies powered by advanced dual-target strategies. The company’s integrated AI platforms play a crucial role in this development, ensuring efficient research and development processes from discovery to manufacturing.
Dr. Michelle Xia, founder and CEO of Akeso, remarked on the company’s 2025 achievements, stating, "This year marked a significant leap for Akeso in commercialization, global clinical expansion, and broadening our multi-platform innovation ecosystem. We are now set to pioneer new therapeutic paradigms by leveraging our leadership in bispecifics and expanding into innovative treatment modalities across various medical fields."
As Akeso continues to progress towards becoming a leader in the biopharmaceutical industry, it remains focused on delivering untapped therapeutic benefits to patients globally, ensuring its position as an innovative powerhouse in the development of groundbreaking medicines. With a robust pipeline of over 50 assets, including 27 candidates undergoing clinical trials, Akeso is committed to paving the way for future advancements in medicine and addressing critical healthcare challenges worldwide.
In summary, Akeso’s 2025 annual report not only highlights remarkable sales growth and strategic excellence but also underscores its ongoing commitment to innovation, enhancing patient outcomes, and leading a transformative change in the biopharmaceutical landscape.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.